Drugs in Dev. Cardiology/Vascular Diseases
Phase I
United Kingdom 
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : $570.0 million
Deal Type : Collaboration
Silence Achieves $10 Million Milestone from AstraZeneca for Phase 1 Trial
Details : Silence and AstraZeneca will collaborate to use Silence’s mRNAi GOLD platform to develop siRNA therapeutics for various diseases, including cardiovascular and respiratory.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $80.0 million
February 23, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : $570.0 million
Deal Type : Collaboration
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Medpace, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This first-in-human study is investigating the safety, tolerability, pharmacokinetic and pharmacodynamic response of SLN360 in people with elevated Lp(a) levels approximately ≥60 mg/dL.
Product Name : SLN360
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 17, 2021
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Medpace, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results presented show that the distribution of SLN360 is confined to the liver (target organ) and kidney (route of elimination) as intended, with levels of SLN360 in other organs (including reproductive organs) less than 1% of peak liver levels.
Product Name : SLN360
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : Zerlasiran
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : $2,080.0 million
Deal Type : Collaboration
Details : Companies working together to deliver siRNA molecules to liver, breast, lung and other tissues. Within the first three years of the agreement the parties anticipate starting work on five targets.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $60.0 million
March 25, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : $2,080.0 million
Deal Type : Collaboration
Reset All
